Skip to main content

Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI

Connect® Myeloid Disease Registry

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Connect® Myeloid Disease Registry

A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide

Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer

Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer

A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.

Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 174
  • Page 175
  • Page 176
  • Page 177
  • Page 178
  • Page 179
  • Page 180
  • Page 181
  • Page 182
  • …
  • Next page Next
  • Last page Last
Subscribe to